Table 1.
Demographic summary of patient groups (median and range)
| Training groups |
Test groups |
N-test | |||||||
|---|---|---|---|---|---|---|---|---|---|
| TOL | CR | N | TOL-test | CR-test | MIS | STA | AR | ||
| Number | 5 | 11 | 8 | 12 | 11 | 10 | 12 | 14 | 8 |
| Age, years | 67 | 56 | 23 | 37.5 | 52 | 55.5 | 49 | 20 | 46 |
| 58–73 | 28–75 | 11–27 | 20–87 | 10–59 | 28–83 | 31–67 | 16–24 | 30–66 | |
| % Male | 80 | 63.60 | 37.5 | 75 | 63.6 | 54.50 | 58 | 64.20 | 0 |
| Time post-transplant, months | |||||||||
| Mean | 178 | 59 | NA | 137 | 48 | 139.5 | 172 | 12 | NA |
| Range | 108–360 | 20–158 | 86–372 | 11–158 | 47–262 | 48–269 | 0.5–108 | ||
| Serum creatinine, μM/liter | |||||||||
| Mean | 122 | 244 | NA | 115 | 244 | 98.5 | 107 | 152 | NA |
| Range | 82–139 | 127–492 | 70.4–149.6 | 100–686 | 64–161 | 63–147 | 110–704 | ||
| Proteinuria per day, g/24 h | |||||||||
| Mean | 0.83 | 1.93 | NA | 0.225 | 2.71 | 0.15 | 0.11 | 0.9 | NA |
| Range | 0–1.28 | 0.34–11.75 | 0.0–1.42 | 0.56–11.75 | 0–0.77 | 0–0.35 | 0.3–1.9 | ||
| Prior AR, % | 20 | 36 | NA | 58 | 63.6 | 9 | 16.60 | 57 | NA |
| Prior CA, % | 20 | 0 | NA | 17 | 0 | 72.50 | 16.60 | 0 | NA |
| Prior CMV, % | 0 | 27 | NA | 0 | 1 | 9 | 0 | 0 | NA |
| HLA incompatibilies | |||||||||
| Mean | 3.2 | 3 | NA | 3 | 2 | 2 | 3 | 3 | NA |
| Range | 3–4 | 1–5 | 2–4 | 2–5 | 0–5 | 0–4 | 2–5 | ||
| LRD, % | 0 | 0 | NA | 0.8 | 36.3 | 0 | 9 | 64.20 | NA |
CA, cancer; NA, not applicable; LRD, living related donor.